Advice
Following a resubmission.
Temozolomide (Temodal®) is accepted for restricted use within NHS Scotland for the treatment of newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and subsequently as monotherapy treatment.
In a three-year follow up of the pivotal phase lll study, a significant survival benefit was seen over placebo in patients with good performance status and favourable prognostic markers.
Temozolamide is restricted to patients who have had a partial or complete macroscopic resection of their tumour and with World Health Organisation (WHO) performance status 0 or 1.
Download detailed advice100KB (PDF)
Medicine details
- Medicine name:
- temozolomide 5, 20, 100 and 250mg capsules (Temodal)
- SMC ID:
- 244/06
- Indication:
- Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and subsequently as monotherapy treatment
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 11 December 2006